Cabozantinib

Cabozantinib is a multi-targeted tyrosine kinase inhibitor that inhibits VEGFR-1/2/3, MET, AXL, and RET. It is approved for renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. Mediocon Inc supplies pharmaceutical-grade Cabozantinib tablets and API meeting IP/BP/EP/USP standards.

Key Features

• Multi-targeted kinase inhibitor (VEGFR, MET, AXL, RET)
• IP/BP/EP/USP compliant quality
• Renal cell and hepatocellular carcinoma treatment
• Available as 60 mg oral tablets

Applications

• Renal cell carcinoma tablets
• Hepatocellular carcinoma therapy
• Differentiated thyroid cancer treatment
• Oncology tablet manufacturing

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings